Literature DB >> 18455721

Relaxations to beta-adrenoceptor subtype selective agonists in wild-type and NOS-3-KO mouse mesenteric arteries.

Khaled Al Zubair1, Sotiria Bexis, James R Docherty.   

Abstract

We have investigated the role of nitric oxide (NO) in relaxations to beta-adrenoceptor agonists in mesenteric artery from wild-type (WT) and NO synthase-3 knockout (NOS-3-KO) mice. Isoprenaline, formoterol and BRL 37344 ((R(),R())-(+/-)-4-[2-[(2-(3-chlorophenyl)-2-hydroxyethyl)amino]propyl]phenoxyacetic acid) were chosen as non-selective and beta(2)- and beta(3)-adrenoceptor agonists, respectively. Atenolol, ICI 118,551 ((+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol hydrochloride) and SR59230A (1-(2-ethylphenoxy)-3-[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanol hydrochloride) were chosen as selective beta(1)-, beta(2)- and beta(3)-adrenoceptor antagonists, respectively. Experiments employing isoprenaline were carried out in the presence of prazosin (0.1 microM). Isoprenaline produced relaxations with a potency of 5.68+/-0.36 (-log M, n=6) in WT mice. Relaxations to isoprenaline were blocked by atenolol (10 microM) and were absent in vessels from NOS-3-KO animals. Formoterol produced relaxations with two components. ICI 118,551 (1 microM) abolished relaxations to low concentrations of formoterol (0.1-10 microM), but failed to affect relaxations to formoterol (100 microM). In NOS-3-KO mice only the highest concentration of formoterol (100 microM) produced relaxations: the relaxation was resistant to all of the beta-adrenoceptor antagonists employed. BRL 37344 (5.75+/-0.28, n=9) was approximately equipotent with isoprenaline but produced a smaller degree of relaxation, in WT mice. SR59230A (1 microM) abolished relaxations to BRL 37344 in WT mice. In NOS-3-KO mice, BRL 37344 produced concentration-dependent relaxations which were abolished by SR59230A. It is concluded that the predominant beta-adrenoceptor mediating relaxations in mouse mesenteric artery is beta(1), and relaxations involve NOS-3. In addition, beta(3)-adrenoceptors mediate smaller relaxations at least partly independent of NOS-3, and beta(2)-adrenoceptors may mediate smaller relaxations dependent on NOS-3.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18455721     DOI: 10.1016/j.ejphar.2008.03.018

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

Review 1.  Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies.

Authors:  Chantal Gauthier; Bertrand Rozec; Boris Manoury; Jean-Luc Balligand
Journal:  Curr Heart Fail Rep       Date:  2011-09

2.  In vivo noninvasive characterization of brown adipose tissue blood flow by contrast ultrasound in mice.

Authors:  David M Baron; Maeva Clerte; Peter Brouckaert; Michael J Raher; Aidan W Flynn; Haihua Zhang; Edward A Carter; Michael H Picard; Kenneth D Bloch; Emmanuel S Buys; Marielle Scherrer-Crosbie
Journal:  Circ Cardiovasc Imaging       Date:  2012-07-09       Impact factor: 7.792

3.  Impaired β-adrenoceptor-induced relaxation in small mesenteric arteries from DOCA-salt hypertensive rats is due to reduced K(Ca) channel activity.

Authors:  Takayuki Matsumoto; Theodora Szasz; Rita C Tostes; R Clinton Webb
Journal:  Pharmacol Res       Date:  2012-02-21       Impact factor: 7.658

4.  Role of alpha 1- and beta 3-adrenoceptors in the modulation by SR59230A of the effects of MDMA on body temperature in the mouse.

Authors:  Sotiria Bexis; James R Docherty
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

Review 5.  Nitric oxide in cellular adaptation and disease.

Authors:  Benjamin N Gantner; Katy M LaFond; Marcelo G Bonini
Journal:  Redox Biol       Date:  2020-04-25       Impact factor: 11.799

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.